Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulating the progression in IgA nephropathy.

James C M Chan1, Howard Trachtman

  • 1University of Vermont and the Barbara Bush Children's Hospital, Maine Medical Center, Portland, Me 04102-3175, USA. chanj@suscom-maine.net

Nephron. Clinical Practice
|June 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Air pollution and disease progression among patients with primary glomerular disease: an expanded study with extended follow-up.

Environmental health : a global access science source·2026
Same author

Sparsentan Versus Irbesartan in Pediatric Patients With FSGS.

Kidney international reports·2026
Same author

Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design.

Glomerular diseases·2026
Same author

Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.

Pediatric nephrology (Berlin, Germany)·2026
Same author

TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.

Lancet (London, England)·2026
Same author

Patient-Focused Drug Development in Kidney Disease: Including Fit-for-Purpose Outcomes in Trials.

Journal of the American Society of Nephrology : JASN·2026
Same journal

Proceedings of the 5th Annual UAB-UCSD O'Brien Center Symposium, March 4, San Diego, California.

Nephron. Clinical practice·2015
Same journal

Proceedings of the 19th International Conference on Continuous Renal Replacement Therapies, March 2-3, 2014, San Diego, California, USA.

Nephron. Clinical practice·2015
Same journal

Chronic kidney disease in disadvantaged populations.

Nephron. Clinical practice·2015
Same journal

Differential membrane expression of Toll-like receptors and intracellular cytokine induction in peripheral blood monocytes of patients with chronic kidney disease and diabetic nephropathy.

Nephron. Clinical practice·2015
Same journal

Correction of hyper- and hyponatraemia during continuous renal replacement therapy.

Nephron. Clinical practice·2015
Same journal

Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction.

Nephron. Clinical practice·2015
See all related articles

IgA nephropathy is a common kidney disease often diagnosed late. This review covers its presentation in young people and treatment options to slow disease progression.

Area of Science:

  • Nephrology
  • Immunology

Background:

  • Immunoglobulin A (IgA) nephropathy affects nearly 1% of the global population.
  • Diagnosis is frequently delayed, contributing to disease progression.
  • A significant percentage (25%) of patients develop end-stage kidney disease within 25 years.

Purpose of the Study:

  • To review the clinical presentations of IgA nephropathy in pediatric and young adult populations.
  • To discuss current and potential therapeutic strategies for managing IgA nephropathy progression.

Main Methods:

  • Literature review of clinical presentations and therapeutic interventions for IgA nephropathy.
  • Synthesis of data on treatment efficacy and progression modulation.

Main Results:

Related Experiment Videos

  • IgA nephropathy presents with diverse clinical manifestations in younger individuals.
  • Multiple therapeutic avenues exist, including ACE inhibitors, steroids, and lifestyle interventions.
  • Combination therapies may offer enhanced modulation of disease progression.

    • Conclusions:

    • Early recognition of IgA nephropathy in children and young adults is crucial.
    • A range of treatments can be employed to slow the progression of this kidney disease.
    • Further research into optimal therapeutic combinations is warranted.